Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ucb SA

UCB.BR ✓ COMPLIANT ☆ Track — members

Euronext Brussels · Healthcare · Pharmaceuticals ·

Belgium Large Cap Analyst: BUY

Last Close

$258.92

▲ +1.74%

Market Cap $50.36B · Vol 253.94K

Key Metrics

P/E Ratio

19.61

FWD: 17.53

Market Cap

$50.36B

Large Cap

Div Yield

0.65%

Annual dividend

EPS Growth

+10.49%

YoY

RSI (14)

50.37

Momentum

Beta

0.91

vs Market

52W High

$338.11

24.03% below

52W Low

$223.30

15.73% above

Volume

253.94K

Avg 222.35K

P/B

4.18

Price-to-book

ROE

18.19%

Return on equity

Free Float

62.94%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ucb SA (UCB.BR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does UCB.BR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.43%

-9.10%

-7.97%

-19.70%

YTD

-7.08%

+11.41%

+190.40%

+123.89%

Financials & Valuation

TTM · Annual

Total Revenue	$9.09B
Net Income	$1.83B
Revenue Growth (YoY)	+22.45%
Gross Margin	74.29%
Operating Margin	25.64%
Net Profit Margin	20.13%
ROE	18.19%
ROA · ROIC	10.26% · 12.74%

P/E Ratio	19.61
Forward P/E (FY1)	17.53
PEG Ratio	0.64
P/S	5.99
P/B	4.18
P/FCF	27.03
EPS Growth	+10.49%
Outstanding Shares	194.51M

Technical Indicators

50-Day SMA	$279.82
200-Day SMA	$289.03
RSI (14)	50.37
Beta	0.91
52-Week High	$338.11
52-Week Low	$223.30

Volume Today	253.94K
Avg Daily Volume (30D)	222.35K
Relative Volume	1.14x
Volatility (10D)	23.56
Volatility (30D)	47.18
Free Float	62.94%

Analyst Consensus

BUY

Current Price $258.92

Mean Target $327.67

52W Low$223.30 52W High$338.11

Current

Target

$223.30 $338.11

Current Analyst target

+26.55% upside potential · 20 analysts

Identifiers

ExchangeEuronext Brussels

FIGIBBG001S6LBX9

ISINBE0003739530

CountryBelgium

Sub-IndustryBiopharmaceuticals

Earnings DateFeb 24, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc +0.90% CSL.AX CSL Ltd -1.69% 207940.KS Samsung Biologics Co Ltd -1.46% BIIB Biogen Inc +1.13% INCY Incyte Corp +0.46%

Company Profile

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.